BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy

March 30, 2017

Strategic decisions made early in clinical development often have an impact on the downstream commercial potential of an asset. This is true for both large pharma and emerging biotech companies. What choices must be made during early clinical development? What are the trade-offs to consider? How do these key decisions affect the commercial potential, partnering opportunities, and ability to invest in other assets in a therapeutic franchise or overall pipeline?

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations
BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations

The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on...

Next Video
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones
BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its...